Early motor function after local treatment of brain metastases in the motor cortex region with stereotactic radiotherapy/radiosurgery or microsurgical resection: a retrospective study of two consecutive cohorts

Table 3 Pre-treatment demographics, oncological data, and motor status of patients with central metastasis, based on the treatment modalities, namely, MRS or SRS/SRT

	Overall	MRS	SRT/SRS	p
Treatments	68	27	41
Patients (n)	64	27	37
Females (%)	52%	52%	52%	n.s.
Age (years)	59.5	60	59	n.s.
RPA	1.83	1.85	1.81	n.s
KPI pre-operative *	78	80	78	n.s
Tumor-Volume (cm³) *	7.2	10.5	4.9	<0.02
Patients with Hemiparesis	36	24	12	<0.005
Muscle strength (BMRC)*:
Arm	4.3	3.7	4.7	<0.008
Leg	4.6	4.3	4.8	<0.0005
NSCLC	43%	44.4%	42.4%	n.s
Mamma-Ca	14.5%	18.5%	11.9%	n.s.
Melanoma	13%	18.5%	9.5%	n.s.
Renal Cell Ca	5.8%	0%	9.5%	n.s.
CUP	5.8%	0%	9.5%	n.s.
SCLC	4.3%	0%	7.1%	n.s
Germ Cell Ca	4.3%	7.4%	2.4%	n.s.
Gastrointestinal Ca	4.3%	3.7%	4.8%	n.s.
Urothelial Cell Ca	2.9%	3.7%	2.4%	n.s.
Sarcoma	1.4%	3.7%	0%	n.s.

SRT/SRS Stereotactic radiotherapy or radiosurgery, MRS Microsurgery, KPI Karnofsky performance index, RPA Recursive partitioning analysis, BMRC British Medical Research Council, NSCLC Non-small cell lung cancer, SCLC small cell lung cancer, Ca Carcinoma, CUP: Carcinoma of unknown primary, n.s not significant
* mean value

ISSN: 1748-717X